DCN and cancer: In addition, the binding of recombinant VAR2CSA to cancer cells (SW480), patient plasma, or decorin is abolished if the samples were treated with chondroitinase before binding analyses (Fig. 2d and Supplementary Fig. 2c), indicating the specific binding of recombinant VAR2CSA.